Seroatlas · Human Serome Atlas

CNPY2

Protein canopy homolog 2

Also known as: CNPY2_HUMAN, HP10390, TMEM4, ZSIG9

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9Y2B0
Gene: CNPY2
Ensembl: ENSG00000257727
Chromosome: 12
Canonical length: 182 aa
Protein class: Plasma proteins, Predicted intracellular proteins
Subcellular location: Cytosol
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Predicted to be active in endoplasmic reticulum. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

182 residues, UniProt reviewed canonical sequence.

>Q9Y2B0|CNPY2
     1  MKGWGWLALL LGALLGTAWA RRSQDLHCGA CRALVDELEW EIAQVDPKKT IQMGSFRINP
    61  DGSQSVVEVP YARSEAHLTE LLEEICDRMK EYGEQIDPST HRKNYVRVVG RNGESSELDL
   121  QGIRIDSDIS GTLKFACESI VEEYEDELIE FFSREADNVK DKLCSKRTDL CDHALHISHD
   181  EL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CNPY2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 70 nTPM

Expression across tissuesHPA

Tissue

epididymis: 70 nTPM
choroid plexus: 66 nTPM
liver: 63 nTPM
pituitary gland: 62 nTPM
pancreas: 51 nTPM
salivary gland: 49 nTPM

Single-cell type

extravillous trophoblasts: 502 nCPM
migrating cytotrophoblasts: 213 nCPM
cytotrophoblasts: 199 nCPM
epididymal principal cells: 194 nCPM
syncytiotrophoblasts: 177 nCPM
plasma cells: 157 nCPM

Immune cell

MAIT T-cell: 78 nTPM
total PBMC: 77 nTPM
memory B-cell: 74 nTPM
memory CD8 T-cell: 72 nTPM
plasmacytoid DC: 72 nTPM
NK-cell: 71 nTPM

Brain region

choroid plexus: 38 nTPM
white matter: 25 nTPM
hypothalamus: 24 nTPM
medulla oblongata: 23 nTPM
spinal cord: 22 nTPM
basal ganglia: 21 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CNPY2.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 35 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Abnormality of the face
Craniosynostosis syndrome

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.94
gnomAD pLI: 0
gnomAD missense Z: 0.65
DepMap mean gene effect: -0.23
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

endoplasmic reticulum

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CNPY2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

MYLIP

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CNPY2 as an antibody target. Whether an autoantibody or antibody against CNPY2 could matter depends on whether native CNPY2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CNPY2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CNPY2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...